To investigate whether the frequency of the BRAF V600E (V-raf murine sarcoma virus oncogene homolog B1) mutation in melanocytic nevi is associated with sun exposure patterns, we examined 120 acquired melanocytic nevi excised from various anatomic sites, including glabrous skin, as well as 62 congenital nevi. We used a new mutation detection system based on the shifted termination assay, called Mutector, which was able to detect only 5% of heterozygous mutant cells within the samples. We detected the mutation in 105/120 (87.5%) acquired nevi and 43/62 (69.4%) congenital nevi. Notably, we found the mutation in 35/43 (81.4%) acquired nevi excised from glabrous skin and genitalia. These results strongly suggest that UV light is not necessarily required for the acquisition of the BRAF V600E mutation, and suggest that non-mutagenic effects of UV light to melanocytes may be more important in the nevogenesis. Additionally, we showed heterogeneous distribution of BRAF-mutated cells within the lesions of small congenital nevi by a combination of laser microdissection and direct sequencing. Finally, we found low frequency of BRAF V600E mutation (6/20, 30.0%) in medium-sized congenital nevi. Most of these nevi with wild-type BRAF had neroblastoma ras viral oncogene homolog mutations (9/14, 64.3%), suggesting different pathogenesis of medium-sized congenital nevi from acquired nevi and small congenital nevi.
INTRODUCTION
Melanocytic nevus and cutaneous malignant melanoma are both melanocytic neoplasia, which have common genetic and environmental risk factors. Individuals with fair skin, with a tendency to sunburn, and those who do not tan are at an increased risk for cutaneous melanoma (Bataille, 2003) , and so are those with an increased number of melanocytic nevi (Bauer and Garbe, 2003) . Numerous epidemiological studies have suggested that the number of melanocytic nevi is the major risk marker for the development of cutaneous melanoma (Bauer and Garbe, 2003) . Sun exposure, particularly before the age of 20, has been suggested to play a role in melanoma development (Elwood and Jopson, 1997) , and also has a major role in the genesis of acquired melanocytic nevi (Gallagher and McLean, 1995) . The relationship between sunlight exposure and the development of these melanocytic neoplasms, however, is complex, and cannot be fully explained simply on the basis of lifetime sun exposure. For example, melanomas frequently occur on skin covered by clothing (Gallagher and McLean, 1995; Elwood and Jopson, 1997) , and indoor workers often suffer higher rates of melanoma than outdoor workers (Elwood and Jopson, 1997) . Although the nevus density is higher on continuously versus intermittently exposed body sites, it peaks at earlier ages, around 9-14 (Gallagher and McLean, 1995) . These apparent paradoxes might be explained by understanding the molecular genetic events that translate the effect of solar exposure into the development of melanomas and nevi.
Recently, a high frequency of oncogenic BRAF (V-raf murine sarcoma virus oncogene homolog B1) mutations at a single site in the kinase domain of the exon 15 has been reported in melanomas and melanocytic nevi, suggesting that the mutational activation of the RAS/RAF/MEK/ERK pathway is a critical step in the development of these melanocytic tumors (Davies et al., 2002; Pollock et al., 2003) . This T to A transversion at codon 600 of the BRAF gene, resulting in a V600E amino-acid missense mutation, would be useful to investigate the etiological relevance of UV light to the genesis of melanocytic neoplasia. However, the relationship between the BRAF V600E mutation and sun exposure is not clear either, because the mutations do not have the standard UVB signatures, such as those in the p53 gene frequently found in non-melanoma skin cancers (Sarasin, 1999) . Furthermore, a recent investigation examining the distribution of BRAF mutations across different melanoma types showed that BRAF mutations were most commonly found in melanomas on skin subject to intermittent sun exposure than elsewhere, and that mutation frequencies were low in anatomic areas that receive the lowest (mucosa and glabrous skin) and the highest sun exposure (face) (Maldonado et al., 2003) . These findings raise the interesting possibility that there may exist several distinct genetic pathways leading to melanoma in relation to sun exposure (Rivers, 2004) . However, whether the same pattern of the uneven distribution of BRAF mutations depending on sun exposure exists in melanocytic nevi is not known.
To further understand the relationship between BRAF mutations, sun exposure, and the development of melanocytic neoplasia, we have examined BRAF mutations in 120 acquired nevi excised from various anatomic sites with different levels of sun exposure. We have also examined 62 congenital nevi that must have developed independently of UV light. Although several previous studies have reported BRAF mutations in different types of melanocytic nevi (Pollock et al., 2003; Uribe et al., 2003; Yazdi et al., 2003; Loewe et al., 2004; Saldanha et al., 2004; Turner et al., 2005) , the present investigation is the first comprehensive mutation analysis examining a large number of cases including both acquired and congenital nevi.
RESULTS
Comparison of sensitivity for detecting the BRAF V600E mutation between direct sequencing and the Mutector assay
To ascertain the sensitivity of direct sequencing and the Mutector assay to detect the BRAF V600E mutation, we performed titration assays (Figure 1 ). Genomic DNA of MM-AN, a melanoma cell line containing heterozygous BRAF V600E mutation, was admixed with blood DNA obtained from a normal individual. Serially diluted DNA samples containing 100-0.01% of the cell line DNA were subjected to direct sequencing and the Mutector assay. Direct sequencing required more than 20% cell line DNA within a given DNA sample to detect the mutation. In other samples, containing less than 20% of cell line DNA, the presence of a mutant peak was not reliably discernable from background spikes. By contrast, the Mutector assay gave positive results when the mutant cell line DNA comprised 5% or more of the mixture. The results confirmed the high sensitivity of the Mutector assay in detecting the BRAF mutation from contaminated samples (Shackelford et al., 2004) .
High frequency of BRAF V600E mutation in acquired nevi, including those from glabrous skin and genitalia
To examine whether the BRAF V600E mutation rates were different according to the anatomical localization, we first analyzed a total of 120 acquired nevi excised from various body sites. Direct sequencing revealed the BRAF V600E mutation in 47 (39.2%) of 120 acquired nevi (Table 1 and  Table S2 ). Although another type of mutation at codon 600 (GTG to GAT) was reported in a melanoma cell line (Davies et al., 2002) , we did not find such mutation. At variance with direct sequencing, the mutation was detected in 105 (87.5%) samples by the Mutector assay (Table 1 and Table S2 ). With the sensitive Mutector assay, we found mutations in most of the samples irrespective of anatomical localizations. All 30 nevi excised from intermittently sun-exposed sites contained BRAF-mutated cells. Notably, 81.4% of acquired nevi excised from non-exposed body sites (i.e., glabrous skin and genitalia) also showed mutation.
We also tested whether other variables, such as patient's age, histological type, and size of nevi, affect the BRAF mutation frequency. The BRAF mutation was detected in 86% (61/71) of patients under the mean age of 37 years old and in 90% (44/49) of patients over 37 years old, respectively. By subgrouping lesions according to size, 85% (55/65) of nevi larger than 6.5 mm and 91% (50/55) of nevi smaller than 6.5 mm, respectively, showed the BRAF mutation. By subgrouping lesions according to histopathological types, we found the BRAF mutation in 89% (17/19) of junctional nevi, in 87% (39/45) of compound nevi, and in 88% (49/56) of dermal nevi. None of these differences were statistically significant.
High frequency of BRAF V600E mutation in small congenital nevi, but low frequency of mutation in medium-sized congenital nevi
In congenital melanocytic nevi, the BRAF V600E mutation frequency differed markedly between small (o1.5 cm) and medium-sized (X1.5 cm) nevi (Table 2 ). Small congenital nevi showed the mutation as frequently as did acquired nevi, the mutation being detected in 61.9% of samples according to the direct sequencing and 88.1% by the Mutector assay, respectively. By contrast, the mutation rate was much lower in medium-sized congenital nevi. Even with the Mutector sequencing and the Mutector assay. Titration assay was performed using genomic DNA samples of a melanoma cell line, MM-AN, which had a heterozygous BRAF V600E mutation, serially diluted with normal blood DNA.
Direct sequencing detected the heterozygous T to A mutation (arrow) in samples containing more than 20% of cell line DNA. Mutector was positive by both visual judgment and the OD ratio (greater than 2.0) in samples containing more than 5% of cell line DNA.
assay, the mutation was detected in only six (30%) of 20 samples. The difference of the mutation rate detected by the Mutector assay between small-and medium-sized congenital nevi was statistically significant (Po0.0001 by the w 2 test). Different from acquired nevi and small congenital nevi, the mutation rates detected by direct sequencing and the Mutactor assay were almost identical in medium-sized congenital nevi. Only one junctional medium-sized congenital nevus on the back of an 11-year-old girl showed discrepant results (Table 3) .
To look for the mutations other than BRAF V600E in medium-sized congenital nevi, we examined mutations of the codon 61 of the NRAS (neroblastoma ras viral oncogene homolog) gene. We found nine mutations at codon 61 (eight Q61 K mutations and one Q61R mutation) ( Table 3 ). All of the cases with NRAS mutations were wild-type for BRAF.
Heterogeneous distribution of BRAF-mutated nevus cells within a lesion
Unexpectedly, we found marked difference in the BRAF mutation frequency between direct sequencing and the Mutector assay in acquired nevi and small congenital nevi (Tables 1 and 2 ). In a total of 154 samples of acquired nevi and small congenital nevi, 60 samples were found to be Back of hand (1) Intermittently exposed sites 30 9-53 (31) M (7) Back (12) Compound (13) 13 17 56.7 0 28 100 F (23) Abdomen (7) Dermal (16) (38.9-74.4) (100-100)
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BRAF mutation positive by both methods. For all 20 samples found to be BRAF mutation negative by the Mutector assay, direct DNA sequencing showed wild-type BRAF. In the remaining 74 samples (48.1%), however, while direct sequencing showed wild type, the Mutector assay was positive. The difference of the results was most prominent in acquired nevi excised from non-exposed sites, in which direct sequencing revealed the mutation in only eight (18.6%) samples (Tables 1, 2 and Tables S2, S3 ). This is not surprising, because 42% of nevi from non-exposed sites were small junctional nevi, from which we were not able to dissect pure nevus cell populations. It appears that the sensitive Mutector assay picked up a small proportion of BRAFmutated nevus cells within the samples admixed with normal keratinocytes, as well as dermal stromal cells. Surprisingly, however, a substantial number of acquired nevi from chronically and intermittently sun-exposed sites as well as small congenital nevi, which showed wild-type BRAF by direct sequencing, were positive for the Mutector assay. These nevi were either compound or dermal nevi, from which relatively pure nevus cell populations were obtained by dissection. Given that the sensitivity of mutation detection by direct sequencing was more than 20% of cells with the heterozygous mutation within the sample, contamination of non-nevus cells was unlikely to account for the discrepant results. To rule out the possibility of technical artifacts, such as PCR contaminations in the Mutector assay, we repeated the assay from the original DNA (not from purified PCR products prepared for direct sequencing) in 14 randomly selected samples (six positive, eight negative), and obtained results completely identical to the original assay. We also tested the 11 DNA samples from normal skin (six of them were from the head and neck) with the Mutector assay, but all of them gave negative results. Thus, the most likely explanation for the discrepant results in these larger nevi is that minor populations of nevus cells with BRAF mutation are present in these lesions, which were detected only with the sensitive Mutector assay. To prove directly this thought, we performed laser microdissection followed by direct sequence in three cases of small congenital nevi. In the initial analyses of DNA samples obtained by macrodissection, all of these three nevi had shown wild-type BRAF by direct sequencing, whereas the Mutactor assay had been positive. We microdissected clusters of nevus cells from 6-12 different areas within the lesions. An example of microdissection and sequence analysis is shown in Figure 2 . Direct sequencing identified BRAF mutation in 2/12 (case 15), 3/6 (case 17), and 4/6 (case 39) microdissected samples, respectively, whereas all the other samples showed wild-type sequence. As shown in Figure 2 , the distribution of areas that showed BRAF mutation was random, and was not related to the localization (i.e., upper dermis or lower dermis) or morphological types (i.e., types A-C) of nevus cells. The result provides direct evidence of clonal heterogeneity of nevus cells within a single lesion in terms of BRAF mutation status, and is very likely to explain the discrepant results between direct sequencing and the Mutector assay in the initial macrodissected samples.
DISCUSSION
It is believed that both melanoma and nevi are caused, at least in part, by excessive exposure to UV irradiation (Jhappan et al., 2003) . Because UV light is a well-known mutagen, it is assumed that the BRAF V600E mutations frequently detected in both melanoma and nevi may be caused directly by UV irradiation. However, the T to A transversion at codon 600, which accounts for more than 90% of mutations of the BRAF gene (Davies et al., 2002) , is not the standard mutation signature of either UVB (Brash et al., 1991) or UVA (Drobetsky et al., 1995) . The BRAF V600E mutations are common in the cells of papillary thyroid carcinoma (Xing, 2005) , a cancer obviously not related to UV exposure. This study also showed a high frequency of the BRAF V600E mutation in congenital nevi and acquired nevi from non-exposed skin, such as soles of the foot and genitalia, both of which must have developed independently of UV light. However, the results should be interpreted with caution, because there is uncertainty about whether all congenital nevi, which were defined by patient's or parent's testimony, were really present at birth, and because there is a chance of UV exposure even on soles of the foot and genitalia. Nevertheless, the high frequency of BRAF V600E mutations in these nevi strongly suggests that UV exposure is not necessarily required for generating BRAF V600E mutations. UV light induces several carcinogenic effects to melanocytes other than direct mutagenesis (Jhappan et al., 2003) . It has been suggested that UV light acts as an independent melanocyte mitogen, directly activating cell surface growth factor receptors by oxidative stress-mediated protein tyrosine phosphatase inhibition (Gross et al., 1999) . UV light also activates melanocortin 1 receptor, which could potentially induce melanocyte growth (Abdel-Malek et al., 1999). Finally, and perhaps most importantly, UV light mediates the upregulation of critical melanocyte growth factors, such as endothelin-1 and basic fibroblast growth factor, originating from adjacent keratinocytes and fibroblasts (Archambault et al., 1995; Tada et al., 1998) . These non-mutagenic effects of UV light to melanocytes may be more important in the development of melanocytic nevi, and are likely to explain the epidemiological link between UV light exposure and the number of melanocytic nevi, although the possibility still remains that the direct mutagenesis of UV light may be responsible for the genesis of acquired nevi on sun-exposed body sites.
Recently, Loewe et al. (2004) retrospectively selected 49 melanocytic lesions, which did not meet the criteria of melanoma at initial presentation. These lesions showed either an increase in size or structural changes after a 12-month follow-up by the use of dermoscopy. Histopathologically, 24 of these lesions were melanoma, whereas the remaining 25 were melanocytic nevi. Samples from these lesions and from 35 randomly selected additional lesions with no change during follow-up were sequenced for their BRAF mutation status. The authors detected BRAF mutations in five of 25 nevi with growth and/or structural change, whereas mutations were found only in two of 35 nevi without morphological changes. Based on this finding, that rapidly growing nevi are more likely to have the BRAF mutation but dormant nevi do not, the authors suggested that BRAF mutation contributes to enhanced nevus growth, and that BRAF mutation may determine lesions at risk of developing into melanoma. However, we found BRAF mutations in the majority of a large series of acquired nevi. The majority of nevi examined in this Samples from areas 2, 3, 4, and 5 showed mutation, whereas those from 1 and 6 were wild-type. The distribution of mutation was not related to the localization or morphological types of nevus cells. Bar ¼ 100 mm. (c) Sequencing traces of DNA extracted from six microdissected areas. Although the initial direct sequencing analysis using macrodissected DNA did not detect mutation, mutant peaks of (A) are apparent in lanes 2, 3, 4, and 5 (arrows), confirming the presence of nevus cells harboring BRAF V600E mutation within this lesion. In contrast, samples dissected from areas 1 and 6 showed wild-type BRAF. Small peaks of (A) are also seen in these two lanes, but they are indistinguishable from noise peaks.
www.jidonline.org 2115 N Ichii-Nakato et al. study were raised nevi, which were unlikely to have shown morphological changes, as well as to develop into melanomas. Thus, our results dispute the view by Loewe et al. (2004) that there may be some link between BRAF mutation and malignancy. Loewe et al. (2004) analyzed mutation by mutation allele-specific PCR and direct sequencing in macrodissected tissues. The difference from the present study in the methods of mutation screening may explain the low mutation frequency in the non-growing nevi reported by Loewe et al. (2004) . Although previous studies by Pollock et al. (2003) and Yazdi et al. (2003) , respectively, found BRAF mutations in 6/7 (86%) and 6/13 (46%) of congenital nevi, the size of nevi analyzed were not described. Papp et al. (1999 Papp et al. ( , 2005 analyzed NRAS and BRAF gene mutations in 18 congenital nevi with known clinical details. These included 15 mediumsized nevi exceeding 1.5 cm in diameter, and found BRAF mutations in six (40%) nevi. We also identified the BRAF V600E mutation in only 6/20 (30%) nevi exceeding 1.5 cm in diameter. The BRAF mutation frequency was significantly lower than that in small congenital nevi (37/42, 88.1%) and acquired nevi (105/120, 87.5%). Interestingly, both studies found a high frequency of NRAS codon 61 mutations in medium-sized congenital nevi, which possessed wild-type BRAF (Papp et al., 1999) , and we, respectively, detected NRAS mutations at codon 61 in 8/9 (88.9%) and 9/14 (64.3%) medium-sized congenital nevi, which were wildtype for BRAF. Most of the NRAS mutations found in both studies were CAA (Glu) to AAA (Lys) mutations (Papp et al., 1999) . These results indicate that mutations of NRAS, rather than BRAF, are common in medium-sized congenital nevi. This difference in the oncogene mutation profiles between small-and medium-sized congenital nevi is interesting, and may have clinical relevance. Generally, a nevus larger than 1.5 cm is very likely a congenital nevus, and, in a lesion of this size, a corroborative parental history that the lesion was present at birth is quite probable. However, small (o1.5 cm) congenital nevi have many overlaps in clinical and histopathological characteristics with acquired nevi, and the evidence, that small nevi represent as congenital were indeed present at birth, is less than compelling (Elder, 1985) . Our data show, also from molecular genetic aspects, that small (o1.5 cm) congenital nevi are similar to acquired nevi, and that medium-sized (X1.5 cm) congenital nevi are distinct from them. NRAS activates both the phosphatidylinositol-3 0 kinase pathway and the mitogen-activated protein kinase pathway, whereas BRAF activates only the latter, suggesting that the NRAS mutations may exert stronger growth signals resulting in the formation of larger nevi. However, there was no difference in the actual size of the congenital nevi between those with BRAF mutations and those with NRAS mutations (Table 3) . It is also of great interest whether this genetic difference between small-and medium-sized congenital nevi may affect their malignant potential. However, currently there is no evidence that the risk of developing melanoma is different between small-and medium-sized congenital nevi (Zaal et al., 2004) . Very recently, Raeve et al. (2006) detected no BRAF mutations in 26 giant congenital nevi, which are definitely associated with increased risk of developing melanoma (Zaal et al., 2004) . It would be very interesting to examine NRAS mutations in giant congenital nevi.
An unexpected finding from the present study is a marked difference in mutation detection between direct sequencing and the Mutector assay in acquired nevi and small congenital nevi. A substantial number of nevi examined in our study showed wild-type BRAF by direct sequencing, whereas the more sensitive Mutector assay were positive. A previous study examining clinical samples from thyroid carcinomas showed 100% concordances of BRAF V600E mutation detection by direct sequencing with the Mutector assay (Xing et al., 2004) . It is unlikely that PCR artifacts such as contaminations may account for the positive Mutector reaction. The most likely explanation for the discrepant results between the two methods is that nevus cells are polyclonal in terms of BRAF mutation status within the lesions of these cases, and that only the sensitive Mutector assay could detect minor populations of cells harboring BRAF mutation. With a combination of laser-capture microdissection and direct sequencing, we convincingly showed that BRAF mutationpositive and -negative nevus cell populations were admixed within the lesions of three small congenital nevi. It is believed that nevi are benign tumors of cutaneous melanocytes (Magana-Garcia and Ackerman, 1990) . Several clonality analyses using PCR-based X-chromosome inactivation assays showed the clonal nature of melanocytic nevi (Robinson et al., 1998; Hui et al., 2001; Indsto et al., 2001) , whereas one study found polyclonal X-chromosome inactivation patterns (Harada et al., 1997) . Furthermore, it was recently suggested that nevi are senescent clones of melanocytes, which temporarily underwent proliferation by concogenic BRAF signaling (Michaloglou et al., 2005) . Most of these previous investigations suggest that nevi are clonal neoplasms. However, our results challenge this notion, and warrant further investigations.
MATERIALS AND METHODS

Tissue samples
Paraffin-embedded tissue blocks of 62 congenital nevi and 120 acquired melanocytic nevi were retrieved from the archives of the Department of Dermatology, Shinshu University Hospital (Matsumoto, Japan) and of the Department of Dermatology, Kanazawa University Hospital (Kanazawa, Japan). All the patients were Japanese. The detailed clinical data of the cases are shown in Tables 1-3 and Tables S2-S3 . We determined the definition of the degree of sun exposure according to the paper by Green (1992) . Hairy scalp and back of the neck of a female were included in the intermittent exposed site. Most of the acquired nevi on chronically or intermittently sun-exposed sites were raised nevi, and excised on request of the patient, mainly for cosmetic reasons. On the other hand, most of the nevi on the palms and soles were flat nevi, and excised for histopathological diagnosis because nearly half of the cutaneous melanoma in the Japanese population arise from glabrous skin (Ishihara et al., 2001) . All the congenital nevi were present at birth according to the medical records at the time of excision. For patients under the age of 18, the presence of the nevus at birth was mostly confirmed by an accompanying parent. According to the classification by Kopf et al. (1979) , 42 of them were small congenital nevi less than 1.5 cm in diameter, whereas the remaining 20 were medium-sized congenital nevi between 1.5 and 19.9 cm in diameter. This retrospective study was approved by the medical ethical committee of the Shinshu University School of Medicine, and conducted according to the Declaration of Helsinki Principles. For excisions, patients gave written informed consent.
Tissue dissection and DNA preparation
We macrodissected nevus cells from 10-mm paraffin-embedded tissue sections using a no. 15 surgical blade, referring to the corresponding hematoxylin-and eosin-stained pathology slides. For dermal nevi and compound nevi with predominant dermal components, the dissection was easy, and the contamination of keratinocytes and stromal cells was estimated to be less than 25%. In contrast, for junctional nevi and small compound nevi, a dissection of relatively pure nevus cell populations was impossible, and whole the epidermis and the papillary dermis, which contained nevus cell nests, were removed for DNA preparation. We extracted DNA using a MagneSil Genomic Fixed Tissue System (Promega, Madison, WI), according to the protocol of the manufacturer.
Laser microdissection
Using a PALM-MB microdissection system (PALM Microlaser Technologies, Bernried, Germany), we obtained a total of 24 samples from three small congenital nevi (cases 15, 17, and 39 in Table S3 ). All of them were dermal nevi. With the initial analyses of DNA samples obtained by macrodissection, these three nevi had shown wild-type BRAF by direct sequencing, whereas the Mutactor assay had been positive. Before microdissection, sections were deparaffinized in xylene, rehydrated in ethanol, and stained with 1% methylene blue. We microdissected several clusters of nevus cells from different parts and different depths of the dermis (Figure 2) . The captured cells were transferred to 10 ml of digestion buffer containing proteinase K and incubated at 501C for 16 hours. Before PCR, proteinase K was inactivated at 901C for 10 minutes.
Mutation analyses for the BRAF gene
To detect the BRAF mutations, we amplified exon 15 of the BRAF gene by PCR. PCR primers are described previously (Davies et al., 2002) . The primer sequences and PCR cycling conditions were given in Table S1 . PCR products were purified with QIAquick (Qiagen, Valencia, CA), and directly sequenced using Big Dye Terminator sequencing chemistry (Applied Biosystems, Foster City, CA) and the sense primer. Sequencing reactions were analyzed on an ABI automated sequencer (Applied Biosystems, Foster City, CA).
Because the use of direct sequencing as the sole method of mutation analysis may miss some mutations in samples with nonnevus cell contamination (Miller et al., 2004) , we also performed a novel and sensitive shifted termination assay, which detects the T to A missense mutation at codon 600 of the BRAF gene, using the Mutector complete kit (TrimGen Co., Sparks, MD) (Shackelford et al., 2004) . In brief, 1 ml of purified PCR products used for direct sequence was re-amplified using a primer pair (Cohen et al., 2004) (Table S1 ), which yielded a 102-bp fragment of exon 15. The amplification was verified with 2% agarose gel electrophoresis. Ten microliters each of the PCR products was subjected to the hybridization with detection primer, primer extension reaction, and colorimetric detection following the manufacturer's protocol. The colorimetric signal was measured with a 405-nm absorbance filter on a microplate reader (Bio-Rad Laboratories, Hercules, CA). A positive result is indicated when the ratio of the optical density of the specimen minus the blank to the optical density of the wild-type control sample minus the blank was greater than two. The results were always concordant with the visual examinations of color development.
Mutation analyses for the NRAS gene
For medium-sized congenital nevi, we also analyzed the mutations at codon 61 of the NRAS gene. PCR primers and amplification protocols for exon 3 (formally designated as exons 2) of the NRAS gene were those described earlier (Davies et al., 2002) . We carried out sequencing in the reverse direction. The mutations at codon 61 were verified by a different nested-PCR method, as described earlier (Houben et al., 2004) (Table S1 ).
Statistical analysis
We used the w 2 test and the Fisher's exact test to examine the difference of the BRAF V600E mutation frequency. A P-value of lower than 0.05 was considered significant.
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